Ventyx biosciences announces positive topline results from phase 2 study of vtx3232 in participants with obesity and cardiovascular risk factors

Vtx3232 demonstrated significant reductions in cardiovascular risk factors, with additional benefits when combined with semaglutide vtx3232 monotherapy achieved ~80% reduction in hscrp within the first week vtx3232 monotherapy reduced il-6 levels at week 12 below the threshold for cardiovascular risk of ≤1.65ng/l 1 statistically significant reductions in lp(a) and liver inflammation no effect on weight either as a monotherapy or as add-on to semaglutide vtx3232 was safe and well tolerated both as a monotherapy and add-on to semaglutide in this study ventyx to hold conference call and webcast 4:30pm et on wednesday, october 22nd san diego, oct. 22, 2025 (globe newswire) -- ventyx biosciences, inc. (nasdaq: vtyx) (“ventyx”, “company”), today announced positive results from its phase 2 study of oral, once-daily vtx3232 in patients with obesity and cardiovascular risk factors. the 175- participant study examined vtx3232 versus placebo, alone or in combination with semaglutide, evaluating safety and tolerability as the primary endpoint, and effects on inflammation (measured by high-sensitivity c-reactive protein or hscrp) as the secondary endpoint.
VTYX Ratings Summary
VTYX Quant Ranking